(Q53147159)

English

Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.

scientific article published on 11 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. (English)

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Kazuaki Chayama

14

object named as

Kazuaki Chayama

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

2

object named as

Hiroshi Aikata

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Tomokazu Kawaoka

1

object named as

Tomokazu Kawaoka

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Shoichi Takahashi

13

object named as

Shoichi Takahashi

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Akira Hiramatsu

11

object named as

Akira Hiramatsu

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Takashi Nakahara

4

object named as

Takashi Nakahara

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

9

object named as

Yuko Nagaoki

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

author name string

Eisuke Murakami

3

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Noriaki Naeshiro

5

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Mio Tanaka

6

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Yoji Honda

7

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Daisuke Miyaki

8

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Shintaro Takaki

10

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Koji Waki

12

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

publication date

11 August 2012

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

83

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

4

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

192-200

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Management of hepatocellular carcinoma in Japan

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies?

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein1

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000341347

21 January 2018

Identifiers

10.1159/000341347

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22890083

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53147159&oldid=1891009537"